Feature | September 14, 2012

SCAI Launches Cath Lab AUC and Guidelines App

AUC calculator app is latest addition to SCAI Quality Improvement Toolkit

September 14, 2012 — Coronary revascularization appropriate use criteria (AUC) are now just a click away with the new SCAI Quality Improvement Toolkit (SCAI-QIT) AUC and Guidelines App, launched this week by the Society for Cardiovascular Angiography and Interventions (SCAI).

“The new app is a calculator tool that makes it simple to access the AUC on heart revascularization without having to carry around printed documents,” said Kalon Ho, M.D., FSCAI, architect of the new tool. “While we don’t intend for this tool to replace clinical judgment, we do hope it provides easier access to information that can guide the cath lab team’s decisions.”

Once members of the cardiac catheterization lab team input facts about a patient’s case, the app will indicate where a “typical” case with those same characteristics would fall on a spectrum of “appropriate,” “uncertain” or “inappropriate” for revascularization, as defined by the latest recommendations from leading cardiology societies, including SCAI and the American College of Cardiology Foundation, among others. Interventional cardiologists can then use that information to make recommendations for treatment of individual patients’ symptoms and conditions. 

SCAI’s calculator app also recognizes that complete documentation is essential in today’s healthcare environment. The app providers users with key data, including the relevant AUC scenario number, the indication score, a summary of the patient’s case and a link to a printer-friendly reporting sheet that can be added to the patient’s chart.  

In coming months, SCAI will expand the app with new modules to help healthcare providers access interventional cardiology guidelines and additional AUC, including those for diagnostic cardiac catheterization. Plans are also underway for the app to include options for interfacing with electronic health records (EHR), further assisting providers with documentation.

The AUC and Guidelines App is part of the expanded SCAI-QIT developed by SCAI’s Quality Improvement Committee to provide tools and resources that help both facilities and providers deliver consistent quality care to cath lab patients. Currently tools focus on guidelines and AUC, national database participation, inventory management, pre-procedure activities, operator and staff requirements, procedural quality and best practices, as well as facility and environmental issues. Each tool is regularly updated to incorporate the latest guidelines, regulatory requirements and feedback from the many SCAI Quality Champions who are using the tools in cath labs around the world.

“The SCAI-QIT has become an important resource for continuously improving cath lab quality. Within months of its launch, interventional cardiologists began telling us how SCAI-QIT helps them identify and address opportunities for improvement,” said SCAI Immediate Past President Christopher J. White, M.D., FSCAI. “The new AUC Calculator App is an example of a tool that will help cath lab teams easily access information supportive of high-quality, evidence-based patient care.”

The SCAI-QIT was developed with founding support from Daiichi Sankyo Lilly and support from AstraZeneca.

For more information: www.SCAI-QIT.org

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init